Phase 2 Multiple sclerosis trials recruiting now

All Multiple sclerosis trials, every phase

Other phases for Multiple sclerosis

Phase 2 Multiple sclerosis trials

• A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS)
  NCT07161258 · Phase: Phase 2 · Ages: 10 Years to 17 Years · Sex: All (male and female) · 17 locations
• A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children and Young Adults With Multiple Sclerosis
  NCT04121468 · Phase: Phase 1, Phase 2 · Ages: 10 Years to 25 Years · Sex: All (male and female) · 1 location
• A Study of LTX-002 in Adult Participants With Amyotrophic Lateral Sclerosis
  NCT07660614 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 5 locations
• A Study of Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple Sclerosis
  NCT07776743 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)
  NCT07503873 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 39 locations
• A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
  NCT06782490 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 55 locations
• A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
  NCT07282574 · Phase: Phase 2 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 108 locations
• A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
  NCT06735248 · Phase: Phase 2 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 17 locations
• AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy
  NCT06063850 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 36 locations
• An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis
  NCT06617793 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 18 locations
• Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy
  NCT05359653 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 1 location
• Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
  NCT02521311 · Phase: Phase 2 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 1 location
• BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
  NCT06794008 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 2 locations
• Bacille Calmette-Guérin (BCG) Vaccine In Radiologically Isolated Syndrome (RIS)
  NCT03888924 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Cannabis (THC vs. CBD) in Multiple Sclerosis
  NCT06261489 · Phase: Phase 2 · Ages: 26 Years to 59 Years · Sex: All (male and female) · 2 locations
• Cannabis as a Complementary Treatment in Multiple Sclerosis
  NCT05092191 · Phase: Phase 2 · Ages: 21 Years and older · Sex: All (male and female) · 1 location
• Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).
  NCT05961644 · Phase: Phase 2, Phase 3 · Ages: 30 Years to 65 Years · Sex: All (male and female) · 1 location
• Comparing Telehealth-Delivered CBT-I to Web-Based CBT-I to Enhance Sleep, Reduce Fatigue, and Promote Neuroprotection
  NCT06434571 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques
  NCT02784210 · Phase: Phase 2 · Ages: 18 Years to 120 Years · Sex: All (male and female) · 1 location
• Efficacy of Cognitive Behavioral Therapy for Insomnia to Treat Insomnia Symptoms in Individuals With Multiple Sclerosis
  NCT06428006 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Efgartigimod for the Treatment of Acute Optic Neuritis
  NCT06453694 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
  NCT05532943 · Phase: Phase 1, Phase 2 · Ages: 20 Years to 65 Years · Sex: All (male and female) · 1 location
• First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)
  NCT06351592 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 22 locations
• Home-Based Transcranial Direct Current Stimulation (tDCS) for Depression in Multiple Sclerosis (MS)
  NCT06901687 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis
  NCT07510607 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Illuminating New Paths in the Treatment of Multiple Sclerosis Relapses - Early and Specialized Rehabilitation
  NCT06956326 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• MB-CART2019.1 in Refractory Multiple Sclerosis
  NCT07178431 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 1 location
• MODAFIMS: A Trial to Evaluate Predictors of Response to MODAFinil in Patients With Multiple Sclerosis
  NCT06592352 · Phase: Phase 2 · Ages: 18 Years to 64 Years · Sex: All (male and female) · 1 location
• Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype
  NCT05269628 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
  NCT06463743 · Phase: Phase 2 · Ages: 55 Years to 75 Years · Sex: All (male and female) · 1 location
• Molecular Imaging of NET Using [C-11]MRB-PET in MS
  NCT03207464 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 1 location
• Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial
  NCT04302870 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 22 locations
• Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis
  NCT06890923 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)
  NCT05418010 · Phase: Phase 2 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 2 locations
• Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis
  NCT05740722 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)
  NCT06675864 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 18 locations
• PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases
  NCT02649985 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 85 Years · Sex: All (male and female) · 1 location
• PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS
  NCT07142291 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 22 locations
• Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
  NCT06655896 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 94 locations
• Psilocybin Therapy for Psychological Distress in Palliative Patients
  NCT06782724 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
  NCT07002034 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 32 locations
• Safety and Tolerability of TOP-N53 Applied on Digital Ulcers in Patients With Systemic Sclerosis
  NCT06954597 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
  NCT05395624 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 9 locations
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT7208 in Healthy Participants and MS Patients
  NCT07085507 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME)
  NCT07287202 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 2 locations
• Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
  NCT06081348 · Phase: Phase 2 · Ages: 8 Years to 17 Years · Sex: All (male and female) · 7 locations
• Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
  NCT06170970 · Phase: Phase 2 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 1 location
• Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
  NCT05104983 · Phase: Phase 2 · Ages: 1 Day to 6 Months · Sex: All (male and female) · 22 locations
• Study of COYA 302 for the Treatment of ALS
  NCT07161999 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 25 locations
• Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis
  NCT07220252 · Phase: Phase 2, Phase 3 · Ages: 10 Years to 17 Years · Sex: All (male and female) · 2 locations
• TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis
  NCT03910738 · Phase: Phase 2 · Ages: 18 Years to 55 Years · Sex: Male · 5 locations
• Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis
  NCT07497399 · Phase: Phase 2 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 2 locations
• Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
  NCT03109288 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 120 Years · Sex: All (male and female) · 1 location
• The Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple Sclerosis
  NCT06599307 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• The HIt HArd and hiT Early in Multiple Sclerosis Trial
  NCT07517185 · Phase: Phase 2 · Ages: 18 Years to 50 Years · Sex: All (male and female) · 4 locations
• Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
  NCT07477639 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 2 locations

Common questions

What does Phase 2 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.